https://www.swissbiotech.org/listing/igm-biosciences-and-adc-therapeutics-announce-clinical-collaboration-agreement-to-evaluate-imvotamab-igm-2323-in-combination-with-zynlonta-in-patients-with-relapsed-or-refractory-b-cell-non-ho/